CP and neoplasm: In patients with central nervous system (CNS) tumors, a range of circulating protein (CP) biomarkers have been identified that reflect tumor-specific biological processes and can be used for diagnostic, prognostic, and therapeutic monitoring purposes (Zhou et al., 2024).